Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CM9.0000000000003641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Correlation between cardiovascular magnetic resonance features and clinical characteristics of cardiac involvement in connective tissue diseases.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha 410008.
Objectives: Patients with connective tissue diseases (CTD) have a high incidence of cardiac involvement, which often presents insidiously and can progress rapidly, making it one of the leading causes of death. Multiparametric cardiovascular magnetic resonance (CMR) provides a comprehensive quantitative evaluation of myocardial injury and is emerging as a valuable tool for detecting cardiac involvement in CTD. This study aims to investigate the correlations between CMR features and serological biomarkers in CTD patients, assess their potential clinical value, and further explore the impact of pre-CMR immunotherapy intensity on CMR-specific parameters, thereby evaluating the role of CMR in the early diagnosis of CTD-related cardiac involvement.
View Article and Find Full Text PDFClinical Outcomes of Congenital Hypothyroidism Due to Biallelic Mutations after Levothyroxine Withdrawal.
Thyroid
September 2025
Department of Molecular Diagnostics, Department of Endocrinology, The Core Laboratory in Medical Center of Clinical Research, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
is a major cause of congenital hypothyroidism (CH) in Chinese patients, but clinical outcomes for those with biallelic mutations remain unclear. This study aimed to describe the clinical manifestations of CH due to defect. One hundred eighty-one patients with primary CH were recruited initially and were subjected to genetic screening.
View Article and Find Full Text PDFResearch Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series.
Aliment Pharmacol Ther
July 2025
Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Combining two advanced therapies may improve outcomes in Crohn's disease (CD) refractory to monotherapy. We conducted a descriptive case series of 27 patients with CD who initiated combination therapy with upadacitinib and infliximab (n = 1), risankizumab (n = 17), ustekinumab (n = 3) or vedolizumab (n = 6). At 12 weeks, 24 achieved clinical response and 9 achieved steroid-free remission.
View Article and Find Full Text PDFHepatitis E virus (HEV) has emerged as a major agent of acute viral hepatitis, with zoonotic genotype 4 (HEV-4) representing a public health concern in China. In this study, we integrated province-wide enhanced hepatitis E surveillance data and molecular profiling from Shandong Province of eastern China, 2019-2023, with the aim of elucidating the epidemiology, genetic diversity, and clinical correlations of autochthonous HEV infections. In total, 5826 cases were reported during the study period, with 72.
View Article and Find Full Text PDFEarly prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.
Br J Haematol
September 2025
Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Polyethylene glycol (peg)-asparaginase plays a crucial role in acute lymphoblastic leukaemia (ALL) treatment, yet its associated toxicity often leads to treatment discontinuation, elevating relapse risk. Hypersensitivity with inactivation of asparaginase is common and often associated with severe allergic reactions. This study aims to comprehensively analyse asparaginase enzyme activity (AEA) pharmacokinetics, validate a previously developed pharmacokinetic model based on intravenous administration and evaluate its capability to detect changes in clearance before inactivation in patients treated with intramuscular peg-asparaginase.
View Article and Find Full Text PDF